Italia Markets close in 3 hrs 49 mins

Idorsia Ltd (0RQE.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
12,25-0,29 (-2,28%)
In data: 06:10PM BST. Mercato aperto.
Schermo intero
Chiusura precedente12,54
Aperto12,10
Denaro0,00 x 0
Domanda0,00 x 0
Min-Max giorno12,10 - 12,10
Intervallo di 52 settimane2,87 - 17,80
Volume400
Media Volume102.892
Capitalizzazione1,609B
Beta (mensile su 5 anni)1,03
Rapporto PE (ttm)N/D
EPS (ttm)-4,26
Prossima data utili25 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Idorsia reacquires the world-wide rights to aprocitentan

    Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension.Idorsia will pay Janssen a conditional consideration up to a total cap of CHF 306 millionIdorsia is initiating activities to determine the best approach to maximize the value of aprocitentan. Allschwil, Switzerland – September 6, 2023Idorsia Ltd (SIX: IDIA) today announced that it h

  • GlobeNewswire

    Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value

    Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2023. Business highlights Transaction with Sosei Heptares: Idorsia sells its Asia Pacific (ex-China) operations – including selected license rights to products – for a total consideration of CHF 400 million.Cost reduction initiative with the target of a reduction in cash-burn at headquarters by approximately 50% expected to become f

  • GlobeNewswire

    Idorsia announces a cost reduction initiative to be implemented by the end of 2023

    Ad hoc announcement pursuant to Art. 53 LR In order to give Idorsia the necessary time to realize commercial success – any funds that are raised must be prioritized on activities to maximize their return in the near-term.The cost reduction initiative is dependent on a full portfolio review, potential out-licensing deals, and an employee representative consultation in Switzerland.The company is launching the initiative with the target of a reduction in cash-burn at headquarters by approximately 5